ELANHealthcare · Drug Manufacturers - Specialty & GenericThe 16 Wall Street analysts covering Elanco Animal Health, Inc. hold a median 12-month price target of $30 — +32.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Elanco Animal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Growth (63): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ELAN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +32.5% from it.
Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2026 | Jefferies | Downgrade | Hold | $31 → $24 |
| 16 Oct 2026 | Goldman Sachs | Initiates | Buy | $32 |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | — |
| 6 Aug 2026 | Keybanc | Maintains | Overweight | $29 → $30 |
| 6 Aug 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $31 → $33 |
| 22 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $23 → $26 |
| 22 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 18 June 2026 | TD Cowen | Maintains | Buy | — |
| 18 June 2026 | TD Cowen | Maintains | Buy | $31 → $32 |
| 7 May 2026 | Citigroup | Maintains | Buy | — |
| 7 May 2026 | JP Morgan | Maintains | Overweight | — |
| 15 Apr 2026 | Citigroup | Initiates | Buy | — |
| 25 Feb 2026 | Keybanc | Maintains | Overweight | — |
| 25 Feb 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 24 Feb 2026 | Leerink Partners | Maintains | Outperform | — |
| 19 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 22 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 18 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELAN appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Elanco Animal Health, Inc. returned +1.7% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 48% of US stocks
Cheaper than 48% of US stocks
Cheaper than 23% of US stocks
Higher than 53% of US stocks
Higher than 94% of US stocks
Higher than 72% of US stocks
Higher than 62% of US stocks
Higher than 25% of US stocks
Higher than 41% of US stocks
Higher than 55% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Elanco Animal Health, Inc. has a market value of $11.3B and an enterprise value of $15.0B.
Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: −$199.0M, a −4.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.41.
Free cash flow in the twelve months to 30 June 2026: $379.0M.
Trailing P/E: 377.1×; forward P/E: 17.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Elanco Animal Health, Inc. employs 9,400 people — $534K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Elanco Animal Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Elanco appointed Jamie Preston as executive vice president and chief people officer, effective November 3, 2026. The company said Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard will retire at year-end.
Why it matters — The appointment and planned retirement mark a leadership transition in Elanco’s people function.
Zacks Investment Research says Elanco has an impressive history of earnings surprises and currently has two key ingredients it views as supporting a likely beat in its next quarterly report.
Why it matters — The item highlights expectations around Elanco’s upcoming earnings report, which ELAN watchers may follow.
The supplied text provides only the headline, “What Growing Up on a Farm Taught Elanco's CEO,” and identifies the source as WSJ; it does not include details about the article's content.
Why it matters — The headline indicates the item concerns Elanco's CEO, but without article details its implications for ELAN cannot be assessed.
Elanco Animal Health President and CEO Jeff Simmons outlined the company's growth strategy, product launches, deleveraging plans, and outlook for its pet health and farm animal businesses during the Bank of America Healthcare Conference in London. The presentation highlighted momentum for products including Quattro and Zenrelia.
Why it matters — ELAN watchers would care because the CEO's remarks offer direct insight into the company's strategic direction, new product traction, and debt-reduction plans for both its animal health segments.
Elanco Animal Health, Inc. (ELAN) presented at the Bank of America Global Healthcare Conference 2026, with a transcript of the presentation published by Seeking Alpha. The company participated in the investor conference session.
Why it matters — An ELAN watcher would care because the conference presentation gives management a platform to discuss the company's business and strategy directly with investors and analysts.
The 16 Wall Street analysts covering Elanco Animal Health, Inc. have a median 12-month price target of $30, with estimates ranging from $24 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Elanco Animal Health, Inc., 13 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elanco Animal Health, Inc. 97 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Elanco Animal Health, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +32.5% from the last close, and Ticker Nerd's factor model ranks Elanco Animal Health, Inc. 97 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Elanco Animal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELAN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $34 over the next 12 months.
Elanco Animal Health, Inc. returned +1.7% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock.
The most recent item we track (PRNewsWire, 22 Oct 2026): "Elanco Animal Health Appoints Jamie Preston as Chief People Officer". Elanco appointed Jamie Preston as executive vice president and chief people officer, effective November 3, 2026. The company said Preston brings more than two decades of global HR leadership and workforce innovation experience; Dave Kinard will retire at year-end.
Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock. The company serves veterinarians, pet owners, farmers, and producers across a wide range of species, including dogs, cats, cattle, poultry, swine, and sheep. Elanco Animal Health Incorporated also offers products used in food-animal health and production settings, supporting disease prevention and animal wellbeing in everyday care and commercial agriculture. Headquartered in Indianapolis, Indiana, Elanco Animal Health Incorporated operates as a diversified participant in the global animal health market, with a broad product mix spanning companion animal and farm animal care.
CEO Mr. Jeffrey N. Simmons · 9,400 employees · United States · https://www.elanco.com
